Table II.
MRI, clinical, and neuropsychological data of patients
| Patients | MRI | Side of TL spikes on EEG | Age at seizure onset (years) | Duration of epilepsy (years) | Seizure frequency (P/month) | AEDs | Dichotic listening test | WAIS‐R estimated IQ | Boston naming test (z score) | Verbal fluency test (z score) | Vigilance test (errors) | WMS‐R general memory (z score) | WMS‐R verbal memory (z score) | WMS‐R visual memory (z score) | WMS‐R delayed recall (z score) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Right‐HS group | |||||||||||||||
| 1 | RHA | right | 4 | 30 | 20 | CBZ; CLN | left | 100 | 0.12 | −0.63 | 0 | 1.23 | 1.53 | ‐0,05 | 1,95 |
| 2 | RHA | right | 8 | 24 | 12 | CBZ; CLB | NA | 97 | −4.8 | −0.63 | 0 | 0.4 | 0.68 | ‐0,37 | ‐0,24 |
| 3 | RHA | right | 7 | 36 | 2 | PNT; CLB | left | 86 | −3.39 | −0.19 | 0 | −0.55 | −0.54 | ‐0,76 | ‐1,02 |
| 4 | RHA | right | 0 | 49 | 14 | CBZ; CLB | left | 100 | −2.13 | −0.85 | 1 | 0.46 | −0.02 | 1,68 | ‐0,45 |
| 5 | RHA | right | 19 | 31 | 2 | LMT; CLB | left | 115 | −0.11 | 0.02 | 0 | 2.38 | 2.96 | 0,46 | 3,16 |
| 6 | RHA | right | 6 | 34 | 12 | CBZ; CLB | left | 100 | 1.32 | 0.46 | 1 | 0.9 | 0.77 | 0,63 | 0,48 |
| 7 | RHA | right | 4 | 34 | 30 | CBZ | left | 92 | −1.11 | NA | 0 | −0.04 | 0.07 | ‐0,11 | ‐1 |
| 8 | RHA | right | 4 | 31 | 4 | CBZ; CLB | left | 97 | −0.58 | −0.85 | 0 | 1.29 | 1.07 | 1,04 | 1,88 |
| Left‐HS group | |||||||||||||||
| 1 | LHA | left | 1 | 47 | 2 | OXC; CLB | NA | 94 | −1.26 | −0.85 | 0 | −0.76 | −1.19 | 0.78 | −0.77 |
| 2 | LHA | left | 20 | 22 | 40 | CBZ; CLB | left | 80 | −501 | −1.02 | 1 | −0.23 | −0.22 | −0.24 | −1.3 |
| 3 | LHA | left | 2 | 22 | 6 | CBZ; TPM | left | 88 | −4.49 | −0.85 | 0 | −1.25 | −1.12 | −0.5 | −0.24 |
| 4 | LHA | left | 4 | 29 | 1 | CBZ; PNT; CLB | left | 94 | −2.69 | −0.19 | 0 | −0.83 | −1.55 | 0.59 | −0.65 |
| 5 | LHA | left | 3 | 44 | 5 | CBZ; CLB | left | 89 | −1.27 | 0.46 | 0 | −0.04 | −0.22 | 0.27 | −0.03 |
| 6 | LHA | left | 7 | 26 | 2 | LMT; TPM; CLB | left | 89 | −1 | 1.34 | 0 | −0.04 | −0.09 | 0.01 | −0.59 |
| 7 | LHA | left | 2 | 40 | 4 | CBZ; CLB | left | 80 | −7.97 | −1.64 | 0 | −1.83 | −2.3 | 0.01 | −1.73 |
| 8 | LHA | left | 2 | 18 | 11 | CBZ | left | NA | NA | NA | NA | NA | NA | NA | NA |
| 9 | LHA | left | 4 | 27 | 4 | CBZ | left | 86 | −4.45 | NA | 0 | −1.51 | −1.12 | −1.53 | −3.15 |
| F and | 0.287 | 0.482 | 0.461 | 0.204 | 9.656 | 3.855 | 0.001 | 0.368 | 15.387 | 14.51 | 1.061 | 6.345 | |||
| P values | 0.600 | 0.498 | 0.508 | 0.658 | 0.008 | 0.07 | 0.979 | 0.554 | 0.002 | 0.002 | 0.32 | 0.025 |
TL, temporal lobe; RHA, right hippocampal atrophy; LHA, left hippocampal atrophy; AEDs, antiepileptic drugs; CBZ, carbamazepine; CLB, clobazam; PNT, phenytoin; LMT, lamotrigine; TPM, topiramate; CLN, clonazepam; NA, not available.